Oxgr1 agonists for use in therapies for metabolic disorders
OwnerAndrew D. Howard, Jing Li +1inventors
InventorsAndrew D. Howard, Jing Li, Yun-Ping Zhou
Life of this patent
Estimating the term…
Abstract
Methods for identifying OXGR1 modulator useful for the treatment of diabetes and conditions associated with diabetes are provided. Further provided are methods for treating diabetes and conditions associated with diabetes with an OXGR1 agonist.
Claims16
A method for identifying agents that modulate OXGR1 protein activity comprising:
- (a) contacting a cell expressing on the surface thereof the OXGR1 protein, the OXGR1 protein being associated with a second component capable of providing a detectable signal in response to the activation of OXGR1 protein;
- and
- (b) determining whether the agent agonizes the OXGR1 protein activity by measuring the level of a signal generated from the interaction of the agent with the OXGR1 protein, wherein a change in the signal from that obtained in the absence of the agent identifies the agent as a agonist of the OXGR1 protein activity.
A method of screening a small molecule compound for treating diabetes and conditions associated with diabetes, comprising screening a test compound against a target of the gene products encoded by OXGR1.
A method for increasing insulin secretion comprising administering to a patient in need thereof a therapeutically effective amount of an OXGR1 agonist in a pharmaceutically acceptable carrier.
A method for enhancing a treatment for diabetes comprising administering to a patient under going treatment for diabetes or a condition associated with type 2 diabetes a therapeutically effective amount of an OXGR1 agonist in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.